The molecular structure and role of LECT2 or CHM‐II in arthritis, cancer, and other diseases

Leukocyte cell‐derived chemotaxin‐2 (LECT2 or LECT‐2), also called chondromodulin II (ChM‐II or CHM2) plays a versatile role in various tissues. It was first identified as a chemotactic factor to promote the migration of neutrophils. It was also reported as a hepatokine to regulate glucose metabolism, obesity, and nonalcoholic fatty liver disease. As a secreted factor, LECT2 binds to several cell surface receptors CD209a, Tie1, and Met to regulate inflammatory reaction, fibrogenesis, vascular invasion, and tumor metastasis in various cell types. As an intracellular molecule, it is associated with LECT2‐mediated amyloidosis, in which LECT2 misfolding results in insoluble fibrils in multiple tissues such as the kidney, liver, and lung. Recently, LECT2 was found to be associated with the development of rheumatoid arthritis and osteoarthritis, involving the dysregulation of osteoclasts, mesenchymal stem cells, osteoblasts, chondrocytes, and endothelial cells in the bone microenvironment. LECT2 is implicated in the development of cancers, such as hepatocellular carcinoma via MET‐mediated PTP1B/Raf1/ERK signaling pathways and is proposed as a biomarker. The mechanisms by which LECT2 regulates diverse pathogenic conditions in various tissues remain to be fully elucidated. Further research to understand the role of LECT2 in a tissue tropism‐dependent manner would facilitate the development of LECT2 as a biomarker for diagnosis and therapeutic target. Leukocyte cell‐derived chemotaxin‐2 (LECT2 or LECT‐2), also called chondromodulin II (ChM‐II or CHM2), plays a versatile role in various tissues. Recently, LECT2 was found to be associated with the development of rheumatoid arthritis and osteoarthritis, involving the dysregulation of osteoclasts, mesenchymal stem cells, osteoblasts, chondrocytes, and endothelial cells in the bone microenvironment. Here, we review the structure and function of LECT2, highlighting its potential as a biomarker and therapeutic target of the disease.